Estabrook A, Kister S J, Hardy M A, Grossbard L, Oster M W, Davis S, Mazoujian G, Haagensen D E
Cancer Immunol Immunother. 1986;23(2):143-7. doi: 10.1007/BF00199821.
Four women with metastatic breast carcinoma and elevated plasma levels of human breast gross cystic disease fluid protein of 15,000 dalton monomer size (GCDFP-15) were treated IV with non-human primate (baboon) anti-GCDFP-15 antibody. Three patients were given a single IV infusion of antibody, while the fourth patient received four sequential IV infusions. Antibody dosage patients, after antibody infusion the plasma level of GCDFP-15 decreased to 0 ng/ml and remained there as long as "free" circulating anti-GCDFP-15 antibody was present. The plasma half-life of the antibody ranged between 1 and 40 h and the duration of detectable free antibody ranged from 6 to 240 h. No toxicity was observed for the dosage range of antibody tested. No anti-baboon antibody response was detected. In the patient who received four sequential infusions of antibody partial regression of subcutaneous metastatic nodules occurred. The other three patients showed no clinically detectable changes from the antibody infusion.
四名转移性乳腺癌患者,其血浆中人乳腺大囊性病液蛋白15000道尔顿单体大小(GCDFP - 15)水平升高,接受了静脉注射非人类灵长类动物(狒狒)抗GCDFP - 15抗体治疗。三名患者接受了单次静脉注射抗体,而第四名患者接受了四次连续静脉注射。抗体剂量方面,抗体输注后,GCDFP - 15的血浆水平降至0 ng/ml,只要存在“游离”循环抗GCDFP - 15抗体,就一直保持在该水平。抗体的血浆半衰期在1至40小时之间,可检测到的游离抗体持续时间为6至240小时。在所测试的抗体剂量范围内未观察到毒性。未检测到抗狒狒抗体反应。在接受四次连续抗体输注的患者中,皮下转移结节出现部分消退。其他三名患者在抗体输注后未出现临床可检测到的变化。